Please ensure Javascript is enabled for purposes of website accessibility

Allergan Waits to Exhale

By Brandy Betz - Apr 16, 2013 at 1:48PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Food and Drug Administration issued another complete response letter for Allergan's migraine inhalant.

Allergan (NYSE: AGN) announced today that the Food and Drug Administration issued a complete response letter for Levadex, an inhalable drug that treats migraines. The company had warning of the FDA's concerns -- which focused not on safety issues but on the drug's manufacturing process -- and has worked to address these problems.

What does this new CRL mean for Levadex's future?

Solving through acquisition
An inspection had turned up a quality issue at the Exemplar Pharma-owned facility that filled the Levadex canisters. So Allergan purchased Exemplar for approximately $20 million and installed its own people for better oversight. The CRL expressed problems with the manufacturing of the completed canisters, but Allergan says the company has already responded and awaits the FDA's review.

It wasn't the first manufacturing CRL that Allergan has received -- or the first acquisition in the name of pushing Levadex toward market. In January, Allergan inhaled its Levadex partner MAP Pharmaceuticals for about $958 million.

Now what?
The FDA will likely perform another inspection on Exemplar, but Allergan's still anticipating a decision in the fourth quarter of this year. Levadex won't suffer a large delay if that timeline holds true, and the setback shouldn't affect Allergen's 2013 revenues.

Levadex could still make it to market next year, joining Allergan's own Botox injection, which has approvals around the world for treating chronic migraines. Levadex won't become the first inhalable migraine drug to market -- Valeant's Migranal nasal spray has been out for years. But Allergan's drug has shown better efficacy.

Allergan can bide its time to approval with its successful approved products. These include the aforementioned Botox, with a predicted $2 billion in revenues this year, and the $870 billion prescription eye drops Restasis.

Foolish final thoughts
It seems that the FDA wants Allergan to iron out these last manufacturing problems before Levadex receives approval. Fortunately for investors, Allergan has other blockbuster products to rely on while this process finishes. And Levadex could end up finding a decent market of migraine sufferers looking for a convenient and effective treatment if it eventually wins approval.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.